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Rapidly evolving RNA viruses, such as theGII.4 strain
of human norovirus (HuNoV), and their vaccines elicit
complex serological responses associated with pre-
vious exposure. Specific correlates of protection,
moreover, remain poorly understood. Here, we
report the GII.4-serological antibody repertoire—
pre- and post-vaccination—and select several anti-
body clonotypes for epitope and structural analysis.
The humoral response was dominated by GII.4-spe-
cific antibodies that blocked ancestral strains or by
antibodies that bound to divergent genotypes and
did not block viral-entry-ligand interactions. How-
ever, one antibody, A1431, showed broad blockade
toward tested GII.4 strains and neutralized the
pandemic GII.P16-GII.4 Sydney strain. Structural
mapping revealed conserved epitopes, which were
occluded on the virion or partially exposed, allowing
for broad blockade with neutralizing activity. Overall,
our results provide high-resolution molecular infor-
mation on humoral immune responses after HuNoV
vaccination and demonstrate that infection-derived
and vaccine-elicited antibodies can exhibit broad
blockade and neutralization against this prevalent
human pathogen.
INTRODUCTION
Human norovirus (HuNoV) is the leading cause of acute gastro-
enteritis, a disease responsible for an estimated 200,000 deaths
per year, mostly in children less than five years old and the
elderly (Collaborators, 2017; Patel et al., 2008). The human nor-Immunity 50, 1530–1541, June 18, 2019 ª 2019 The Author(s). This is 
the CC BY license (http://creativecommons.org/licenses/by/4.0/).ovirus genome is a single-stranded, plus-sensed RNA with 3
open reading frames (ORFs), including an ORF2 major capsid
protein (viral protein 1, VP1) composed of shell and protruding
(P) domains. Expression of VP1 in insect and mammalian sys-
tems leads to self-assembly of 90 VP1 dimers into icosahedral
virus-like particles (VLPs) that are antigenically indistinguishable
from virions (Baric et al., 2002; Green et al., 1993; Jiang et al.,
1995; Prasad et al., 1999). Despite more than 30 known human
norovirus genotypes, 60% of norovirus outbreaks are caused
by GII.4 genotype strains (Burke et al., 2019; Cannon et al.,
2017). Efforts to develop an effective vaccine against human nor-
ovirus are complicated by the large number of antigenically
distinct genotypes and the rapid evolution of GII.4 viruses (Atmar
et al., 2018; Bull et al., 2007; Debbink et al., 2014a; Kocher et al.,
2018; Lindesmith et al., 2008). Increased understanding of which
capsid epitopes should be targeted to protect against different
genotypes and of the impact of pre-exposure history on the elic-
itation of protective immunity after vaccination are important
considerations in vaccine design and efficacy (Havenar-Daugh-
ton et al., 2018; Lindesmith et al., 2015, 2017; Snijder
et al., 2018).
Antigenic drift within GII.4 norovirus strains has prompted
serial pandemic outbreaks in 1995, 2002, 2006, 2009, and
2012, each correlating with the emergence of new GII.4 anti-
genic variants that appeared to have escaped pre-existing
immunity (Debbink et al., 2012b; Lindesmith et al., 2008; Sie-
benga et al., 2007). Human norovirus attaches to the cell
surface via binding to histoblood group antigens (HBGAs;
typically A, B, O, or Lewis antigens) on mucosal surfaces of
the gut (Lindesmith et al., 2003; Tan and Jiang, 2011). Exten-
sive studies have established that antibodies that block noro-
virus VLP binding to HBGAs strongly correlate with protective
immunity in chimpanzees and humans (Atmar et al., 2011; Bok
et al., 2011; Malm et al., 2014; Reeck et al., 2010). Immune
escape frequently relies on mutations at key residues in the
immunodominant A, D, and E epitopes targeted by blockadean open access article under 
antibodies, with blockade measured by a surrogate neutrali-
zation assay based on the antibody-dependent inhibition
of VLP binding to HBGAs (Debbink et al., 2012a; Harrington
et al., 2002; Lindesmith et al., 2012a, 2012b). Carbohydrate
ligand blockade assays are the primary functional assay
used to predict serological immunity and represent the clinical
endpoint for evaluating norovirus infection and vaccination
outcomes (Atmar et al., 2011; Lindesmith et al., 2015, 2017;
Malm et al., 2014; Reeck et al., 2010). Recent development
of human intestinal enteroids (HIEs) as an in vitro system
that successfully supports the replication of HuNoV also al-
lows for direct evaluation of neutralization (Costantini et al.,
2018; Ettayebi et al., 2016).
Multivalent VLP immunization broadens the breadth of
blockade antibodies produced after immunization of mice (Deb-
bink et al., 2014b; LoBue et al., 2006) and humans (Lindesmith
et al., 2015). Currently, the leading human norovirus vaccine
candidate is in phase IIb clinical trials (Bernstein et al., 2015; Ler-
oux-Roels et al., 2018). This vaccine comprises a mixture of two
VLPs: GI.1, the prototypical genogroup 1 strain, and GII.4c (GII.4
consensus), a VLP based on the consensus sequence of the
GII.4 strains Houston (2002), Yerseke (2006a), and Den Haag
(2006b) (Bernstein et al., 2015; Parra et al., 2012; Treanor
et al., 2014). GII.4.2006a was used as the default sequence
where all three of the strains diverged, most notably within the
evolving immunodominant epitopes A, D, and E. The vaccine
induces rapid (evident at day 7 post vaccination) antibody
responses against both genogroup I and genogroup II VLPs (Lin-
desmith et al., 2015). The rapid blockade antibody response af-
ter vaccination suggests that the vaccinemay activate amemory
B cell or recall response in adults (Lindesmith et al., 2015),
though the mechanisms governing this immune outcome have
remained unknown.
Here, we report on the serological repertoire to the GII.4c
VLP component of the bivalent human norovirus vaccine
pre- and post-immunization. We determined the serological
repertoire using immunoglobulin sequencing (Ig-Seq), a prote-
omics-based serum antibody repertoire analysis methodology
(Georgiou et al., 2014; Lee et al., 2016; Williams et al., 2017).
We focused on the GII.4c component of the vaccine because
GII.4 strains have proven more clinically significant and display
a higher rate of evolutionary drift, which potentially complicates
the elicitation of protective immunity. Our results (1) provide
clear evidence of the dominant effect of pre-existing immunity
arising from earlier exposure on the humoral response to the
vaccine; (2) define three classes of HuNoV circulating anti-
bodies: one class comprising antibodies with very extensive
binding breadth recognizing GI strains and GII strains but hav-
ing no blockade activity, a second class that is specific to GII.4
and has blockade activity towards historical pandemic strains,
and finally, a third class represented by one virus-neutralizing
antibody with potent blockade activity towards historical GII.4
strains and contemporary strains that emerged well after the
strains which were used to design the vaccine GII.4c VLP
and human trials; (3) characterize in molecular detail VP1 epi-
topes that are targeted to enable broad binding or broad
blockade with neutralizing activity, and (4) highlight the impact
of pre-existing serological repertoire breadth and titers on the
response to the vaccine.RESULTS
The GII.4 HuNoV Serological Repertoire after HuNoV
Bivalent Vaccination Is Highly Polarized and Shaped by
Previous GII.4 Infection
We analyzed three donors that experienced a significant increase
in GII.4 titer after immunization with the bivalent GII.4c + GI.1 VLP
vaccine (Figure1A; TableS1). The serological repertoirewasdelin-
eated using Ig-Seq, a proteomic methodology in which serum
antibodies are purified by affinity chromatography against an im-
mobilized antigen—in this case, immobilized GII.4c VLP—then
proteolytically digested into peptides and analyzed by liquid chro-
matography-tandem mass spectrometry (LC-MS/MS). Peptide
spectral matches were obtained using a custom database of
heavy-chain-variable (VH) genes encoded by peripheral B cells
from the respective donor. To construct the VH database, periph-
eral bloodmononuclear cells (PBMCs) collected ateach timepoint
weresplit into twoaliquots: onealiquotwassequencedusinghigh-
throughput single-cell flow-focusing technology (DeKosky et al.,
2015; McDaniel et al., 2016) to determine the native VH/VL
(heavy-chain-variable/light-chain-variable) paired repertoire, and
the second aliquot was processed to determine the VH repertoire.
Relative quantitation of serum anti-GII.4c antibodies was deter-
mined from the LC peak intensity of high-confidence peptide-
spectrum matches (PSMs) derived from peptides of the
third complementarity determining region of the heavy chain
(CDR-H3). Antibodies belonging to a CDR-H3 clonotype likely
recognize the same epitope, given the dominant role of CDR-H3
in antigen recognition. As we established earlier, the Ig-Seqwork-
flow identifies the majority (>70%) of the most abundant antigen-
specific antibodies in the serum, and quantitation calibrations
using isobaric peptide spike-ins show that peak intensities corre-
late well with absolute peptide concentrations (Lavinder et al.,
2014). The antibody repertoire composition and relative quantities
at theclonotypic level areplottedasahistogramwitheachbar rep-
resenting an individual clonotype and the horizontal axis showing
its relative abundance (Figure 1B). All three donors had a titer to
GII.4c at day 0, presumably a consequence of prior exposure to
GII.4 infection and consistent with earlier data indicating that the
vast majority of asymptomatic adults have antibodies to HuNoV
(Carmona-Vicente et al., 2015; Nurminen et al., 2011). As has
been the case with the serological repertoire to other antigens re-
ported so far (e.g., influenza hemagglutinin [Lee et al., 2016],
tetanus toxoid [Lavinder et al., 2014], or desmoglin in pemphigus
patients [Chen et al., 2017]), the repertoire to GII.4c was found to
be oligoclonal and highly polarized, in that <3 antibodies domi-
nated the response, contributing more than 50% of the antigen-
specific titer (Figure 1B). In particular, at day 0, the dominant
CDR-H3 clonotype in each repertoire accounted for between
58% and 86% of the total CDR-H3 peptide intensity, suggesting
that the long-term serological memory to GII.4 is dominated by a
single antibody. Other examples of highly skewed serological
repertoire polarization with one clonotype accounting for >60%
of the response have been reported previously (Lee et al., 2016).
Antibody clonotypes present in both the pre-vaccination
repertoire (day 0) and the post-vaccination repertoire were
defined as ‘‘pre-existing,’’ whereas clonotypes observed
exclusively in the post-vaccination repertoire were defined as
‘‘emergent.’’ The term ‘‘emergent antibodies’’ refers only to the
Figure 1. The Anti-NoV GII.4c IgG Serum
Antibody Repertoire following Vaccination
Is Polarized and Shaped by Previous HuNoV
Infection
(A) Donors (n = 3) were immunized with experi-
mental HuNoV vaccine and serum and PBMCs
were collected at the times indicated.
(B) Relative abundance of GII.4c-specific IgG clo-
notypes pre- and post-vaccination. Each bar rep-
resents a CDR-H3 antibody clonotype observed at
a0.5% of the GII.4c antigen-specific antibody
repertoire.
(C) Amount of anti-GII.4c serum antibodies (i.e.,
the product of anti-GII.4c IgG ELISA titer3 relative
antibody abundance as determined by LS-MS/
MS; see STAR Methods) pre- and post-vaccina-
tion; ELISA titer shown over each bar.
(D) Number of detected antibody clonotypes
before and after vaccination.
(E) Anti-GII.4c antibody V-gene somatic hyper-
mutation rates for pre-existing and emergent an-
tibodies; n.s. represents not statistically significant
(two-tailed t test; p > 0.3).
(F) V-gene family usage in the serological repertoire.
Related to Table S1.fact that they become detectable in the serum post vaccination 
and should not be interpreted in terms of B cell ontogeny 
(i.e., whether they arise from stimulated naive cells or memory 
B cells). Although vaccination increased the diversity of the sero-
logical repertoire in all donors, both the number and abundance 
of vaccine-elicited clonotypes were substantially lower in donor 
C, who had a 4- to 5-fold higher titer to GII.4c before vaccination 
(day 0) compared to the other two donors (Figures 1B–1D). In this 
donor, the increase in the GII.4c titer 4 weeks post vaccination 
was overwhelmingly due to the boosting of the dominant anti-
body clonotype C601, which accounted for >90% of the serum 
response and increased in absolute abundance by more than 
7-fold relative to the level observed at day 0. The low level of 
emergent antibodies in donor C, who had the highest pre-vacci-
nation titer, is consistent with the strong inverse correlation be-
tween day 0 serum titer and the number of emergent antibody 
clonotypes in the serological memory after immunization with 
the seasonal influenza vaccine (Lee et al., 2016).
Pre-existing and emergent antibodies displayed similar so-
matic hypermutation profiles (Figure 1E). Although emergentantibodies (7.1 ± 0.5% mean rate of
somatic hypermutation) were slightly
less mutated than the pre-existing anti-
bodies (8.2 ± 1.1%), this difference did
not reach statistical significance. The
anti-GII.4c serological repertoire was
predominantly comprised of antibodies
using the immunoglobulin heavy vari-
able 3 (IGHV3) family (80%; Figure 1F)
compared to 30% in naive or mature
B cells (DeKosky et al., 2016; Mroczek
et al., 2014). These findings suggest
that the serological IgG response to
human norovirus vaccination is largelydominated by the boosting of a limited number of pre-existing
antibody clonotypes.
Recombinant HuNoV Serum Antibodies Demonstrate
Neutralization against GII.4 and Breadth of Binding
across Strains
We expressed and characterized a set of 10 representative
serum antibodies for which both VH and VL sequences were de-
tected by paired VH/VL sequencing. These included the top
most abundant clonotypes in donors A and C (A379 and
C601), two strongly boosted pre-existing clones (A101 and
A1431, boosted by 123 and 1263, respectively, in terms of
abundance in the post-vaccination serum relative to day 0),
and six emergent antibodies (Figure 1B). Binding and blockade
activity were tested using an antigenically diverse panel of noro-
virus genogroup I and genogroup II VLPs, including a time-
ordered panel of pandemic GII.4 VLPs representing historical
variant strains, including US95_96 (GII.4 1997), Farmington Hills
(GII.4 2002), and Den Haag (GII.4 2006b), as well as prospective
strains that emerged following vaccine design (2006) and the
Figure 2. HuNoV Recombinant Serum Antibodies Recognize
Conserved Binding, Ligand-Blocking, and GII.4 Neutralizing Epitopes
Sigmoidal dose response curves were fit to the mean percent control binding
for determination of (A) half-maximum binding (EC50) or (B) half-maximum
blocking of HBGA binding (half-maximum inhibitory concentration, IC50) of
pre-existing (P) and emergent (E) antibodies. Titers >2 mg/mL were scored as
negative (white box). The HBGA blocking assay was used to characterize
A1431 against a panel of pandemic norovirus GII.4 strains. Antibodies wereclinical trial (2010), such as GII.Pe-GII.4 Sydney (GII.4 2012) and
GII.P16-GII.4 Sydney (GII.4 2015) (Lindesmith et al., 2018a). As
expected, all antibodies bound to the vaccine strain VLP (Fig-
ure 2A), with half-maximal effective concentration (EC50) values
between 8 and 717 ng/mL. The potential for neutralization by in-
hibition of cellular ligand binding was evaluated by determining
blockade of VLP-ligand binding (blockade assay) (Figure 2B).
The 10 serumantibodies could be categorized into three classes.
The first class consisted of 6 antibodies that displayed broad
binding but no blocking activity toward multiple GI and GII
strains; three of these, namely A1227, B401, and B404, showed
binding to all strains tested, including a variety of GI and GII ge-
notypes such as GI.I, GII.2, and GII.17. The VP1 protein among
these strains shows only 50% amino acid identity (Zheng
et al., 2006). The second class consisted of antibodies B403,
C601, and C602, which had strong blockade activity towards
the vaccine strain and the earlier pandemic GII.4 1997 strain
but not to GII.4 strains that emerged post vaccination. Finally,
the third class of serum antibodies had a single member,
A1431, which had strong blockade activity to all known historical
GII.4 strains from 1987 onwards. A1431 had very extensive
breadth and potency not only towards all historical strains avail-
able but also towards prospective GII.4 strains that appeared
after the vaccine trial, including GII.4 2012 and 2015, neither of
which had circulated in the general population at the time of sam-
ple collection (Figure 2B). Furthermore, A1431 potently neutral-
ized GII.P16-GII.4 Sydney virus, a GII.4 strain that emerged
5 years post sample collection, in a human intestinal enteroid cul-
ture system (Costantini et al., 2018; Ettayebi et al., 2016) (IC50
5.5 ng/mL), supporting the correlation between blockade of
ligand-binding potency and antibody-mediated neutralization
(Figures 2C and S1) (Alvarado et al., 2018; Ettayebi et al., 2016).
We sought to define biochemically the epitopes recognized by
the antibodies with blockade activity to historical strains, namely
B403, C601, and C602; as discussed below, the epitope of
A1431 that has broad blockade breadth was determined by
crystallography. We first evaluated antibody mediated blockade
against a panel of VLPs with epitopes A, D, and E exchanged
from GII.4 2012 (non-binding VLP) into GII.4 1987 (binding
VLP). Exchange of epitope A residues ablated blockade potency
of B403 and diminished potency of C601 by 13.5-fold but had lit-
tle effect on C602 blockade (1.8-fold decrease). Exchange of
epitope D or E residues had little impact on blockade of any of
the three antibodies, suggesting that the major binding determi-
nants for B403 and C601 likely reside within epitope A (Figures
3A–3C). VLPs displaying an acidic residue at 298, Val at position
356, andHis at 357 had lower EC50 titers than VLPswithout these
residues for all three antibodies (Figures 3B and 3C). Exchange
of V298E/A356V/E357H into the null backbone VLP 581 (Linde-
smith et al., 2018b) (VLP 581.A4A) gained binding of B403 and
C601 and improved binding of C602 by 11.6-fold compared totested in duplicate in a minimum of two independent experiments. (C)
Sigmoidal dose response curves were fit to the mean percent viral genomic
copies control for determination of IC50 in a neutralization assay. The
neutralization assay was used to characterize A1431 and A1227 against the
GII.P16-GII 4 Sydney strain. Error bars represent mean ± SEM from four in-
dependent experiments with 2 technical replicates for each dilution. Related to
Figure S1.
Figure 3. Serum Antibodies that Block His-
torical GII.4 Strains Recognize Overlapping
Epitopes within Epitope A
(A) Homologymodel based onPDB: 3SLD (Shanker
et al., 2011) of the GII.4 2006a P domain dimer of
the HuNoV major capsid protein, VP1 with known
P domain blockade antibody epitopes A (blue),
D (dark gray), E (purple), and F (orange) highlighted.
(B) Amino acid sequences of pandemic strains and
select mutants of GII.4 1987.
(C) Blockade potency binned by IC50.
(D) Select mutants of GII.4 2006a.581 VP1. High-
lighted areas indicate sequences important for
antibody binding.
(E) Antibody binding binned by EC50 values. An-
tibodies were tested in duplicate in a minimum of
two independent experiments.the 581 VLP (Figures 3D and 3E). Substitution of V298N/A356V/
E357H (VLP 581.A4B) did not gain binding for B403, yielded 
similar binding to that to 581.A4A for C601, and decreased 
C602 binding by 7.6-fold compared to 591.A4A. These data 
confirm E or D at position 298 as an anchor residue for B403. 
For antibody C601, binding was heavily influenced by V356/
H357, residues that are predicted to contribute to epitope A 
but have not been previously verified. Further, our analysis also 
revealed that C602 recognizes a previously undefined blockade 
epitope. Together, these data categorize antibodies boosted by 
HuNoV VLP vaccination into three classes: (1) genogroup I and 
genogroup II broadly binding, non-neutralizing antibodies; (2) 
ancestral GII.4 binding and ligand-blocking antibodies; and (3) 
GII.4 broadly binding and neutralizing antibodies. Genetic map-
ping indicated that antibodies displaying a limited breadth of 
GII.4 ligand-blockade potency (class 2 above) recognized the 
immunodominant epitope A antigenic site (Mallory et al., 2019) 
and accounted for previously observed back-boost antibody re-
sponses in HuNoV vaccinated donors (Lindesmith et al., 2015). 
These data demonstrate that HuNoV vaccination can elicit 
serum antibodies capable of neutralizing GII.4 pandemic strains.
Structural Studies Define a Highly Conserved
Non-Blocking Epitope and a Conserved GII.4 
Neutralizing Epitope within the Capsid P Domain
To gain insight into the molecular mechanisms underlying cross-
reactive, non-blockade activity, we selected the pan-reactive 
antibody A1227 for crystallographic analysis. We purified the an-
tigen-binding fragment (Fab) of A1227 in complex with soluble 
GII.4 P domains from 2002, 2006, 2009, or 2012 pandemic 
strains and screened for crystallization. Complexes with theGII.4.2002 P domain (P2002) yielded dif-
fracting crystals suitable for structural
analysis.
Single crystals of the complex between
A1227 and P2002 diffracted to 2.6 Å, and
the structure was solved by molecular
replacement using the apo P2002 struc-
ture (PDB: 4OOV) (Singh et al., 2015) (Ta-
ble S2). A1227 Fab bound to each of the
conserved P1 subdomains of the P2002dimer (Figure 4A). Each Fab bound at the interface between
monomers in the P2002 dimer, with the heavy chain recognizing
both protomers and the light chain recognizing only a single pro-
tomer (Figure 4B). A1227 recognized a region of P2002 which
was mostly conserved across genogroups GI and GII (Figures
4C and S2), thus explaining the broad cross-reactivity of anti-
body A1227. Overall, each Fab buried 950 Å2 by establishing
polar contacts and favorable van der Waals interactions with
P2002 (Figures 4D and S2). There were no substantial conforma-
tional changes upon A1227 binding to P2002, with a root-mean-
square deviation (RMSD) of 0.6 Å between apo-P2002 and
A1227-P2002 complex structures.
To map the A1227 epitope within the context of the VLP, the
crystal structure of the A1227-P2002 complex was superim-
posed onto the GI.1 capsid structure (PDB: 1IHM) (Prasad
et al., 1999). The GI.1 capsid structure was chosen as a template
for modeling due to similarities between GI.1 and GII.4 capsid
structures indicated by prior electron microscopy (EM) studies
(Chen et al., 2004). Modeling revealed that the conserved region
recognized by A1227 was located at an occluded site on the
norovirus capsid, at the interface between the P domain and
shell domain. Overlay of Fab A1227 onto the GI.1 capsid
structure (Figures 4E and 4F) indicated that other P domains
on the assembled norovirus capsid would clash with both
heavy and light chains of the Fab, with only minor clashes with
the shell domains (Figure 4G), suggesting that structural rear-
rangements of the P domain could either expose the A1227 bind-
ing site or allow binding at a neighboring P domain. Its lack of
blockade or neutralizing activity likely results from antibody
A1227 only recognizing defects or maturation intermediates (Po-
gan et al., 2018).
Figure 4. The Broadly Binding Non-Blockade Antibody A1227 Binds to a Highly Conserved Epitope within the P Domain
(A) Crystal structure of A1227 Fab bound to GII.4.2002 P domain dimer shown in cartoon representation, with P domain monomers colored pink and orange and
A1227 heavy and light chains in gray and blue, respectively.
(B) The A1227 antibody binds near the P1 dimeric interface (P domain dimer in surface representation and A1227 Fab in cartoon).
(C) A1227 Fab footprint is outlined in yellow on the P domain surface, mapped by GI-GII sequence conservation, with degree of conservation colored from
variable (white) to conserved (purple).
(D) Detailed view of A1227 Fab-P domain binding interface, with interacting residues depicted in stick and hydrogen bonds shown in yellow dotted lines.
(E) Modelling of the GII.4.2002 P domain-A1227 Fab crystal structure onto the GI.1 capsid structure (PDB: 1IHM) reveals an antibody binding site that is occluded
on the assembled VLP.
(F) Close-up view from (E) showing the occlusion of A1227 Fab within the GI.1 capsid.
(G) Quantification of volume overlap between A1227 Fab (or VH/VL) and GI.1 capsid proteins. Over 60% of the volume of A1227 Fab overlaps with neighboring P
domains when modelled onto either A/B or C/C dimers. Only small overlaps are due to clashing with shell domains. Overlaps from P domain and shell domain are
colored in gray and yellow, respectively. Volumes were calculated using Voss-Void-Voxelator program (Voss and Gerstein, 2010).
Related to Table S2 and Figure S2.To provide a structural basis for recognition by the GII.4
broad blockade antibody A1431, we solved the crystal struc-
ture of A1431 Fab in complex with the GII.4.2002 P domain
at 3.1 Å resolution (Table S2). The asymmetric unit contained
two P-domain-A1431 Fab complexes, with each dimer gener-
ated by crystallographic 2-fold symmetry. Both complexes
were nearly identical, with an RMSD of 0.3 Å. Electron density
for both P2002 and A1431 variable domains was well defined,
although regions of A1431 constant domains were not well
ordered.Antibody A1431 bound each P domain monomer at a cleft be-
tween the P1 and P2 subdomains (Figure 5A). Similar to A1227,
A1431 binding did not induce substantial conformational
changes in the P domain, with an overall RMSD of 0.4 Å between
the complex and apo (PDB: 4OOV) structures. Antibody A1431
recognized an epitope located near previously mapped
blockade epitopes D and F and distinct from the site of HBGA
binding (Figure 5B). Both A1431 heavy and light chains contrib-
uted to the binding interface with a total buried surface area of
985 Å2 on the P domain. The CDR-H3 loop of A1431 was
Figure 5. Broad GII.4-Blockade Antibody A1431 Recognizes an Accessible Semi-Conserved Site of Vulnerability
(A) Overall structure of A1431 Fab bound to GII.4.2002 P domain dimer is shown in ribbon representation, with P domainmonomers in pink and orange and A1431
heavy and light chains in magenta and cyan, respectively.
(B) Mapped blockade epitopes are highlighted on a surface representation of GII.4.2002 P domain dimer (colored as in Figure 3A) with the A1431 Fab shown
in cartoon. The crystal structure of GII.4 (Farmington Hills, 2004) P domain complexed to HBGA type B ligand (PDB: 4X05) was superimposed onto the
GII.4.2002 P domain + A1431 complex to show location of HBGA binding site.
(C) Details of A1431 Fab interactions with P domain residues are highlighted with interacting residues depicted in stick and hydrogen bonds shown in yellow
dotted lines.
(D) A1431 Fab footprint is outlined in yellow on the P domain dimer surface, mapped by GII.4 sequence conservation, with degree of conservation colored from
variable (white) to conserved (purple).
(E) The GII.4.2002 P domain-A1431 Fab crystal structure is modeled onto the GI.1 capsid structure (1IHM; Prasad et al., 1999), with a cross-section showing
the P domain fit onto the A/B dimer (top) or the C/C dimer (bottom). Overlap between A1431 Fab and P domain, as modeled onto either GI.1 capsid A/B or C/C
dimers, is minimal and shown on right, as in Figure 4G.
(F) Modeling of A1431 Fab to the A/B dimer (top) or C/C dimer (bottom) on the GI.1 capsid structure, with A/B dimers colored pink and tan, C/C dimers colored in
gray and shell domain shown in yellow.
(G) GI.1 capsid models, colored as in (F), showing occupancy of A1431 binding sites on all A/B dimers (top) or all C/C dimers (bottom).
Related to Table S2 and Figure S3.inserted into a cleft between the P1:P2 subdomains and was 
held in place by hydrogen bonding between main-chain atoms 
of the CDR-H3 and P domain residues Gln402, Trp403, and 
Gln504 (Figure 5C). Ser30 and Tyr32 from the CDR-L1 loop pro-
vide additional stabilization via hydrogen bonds to Asp506 on theP1 subdomain. The recognized surface, including P domain
residues Gln402, Trp403, Gln504, and Asp506, was nearly
completely conserved in GII.4 (Figure 5D) but only semi-
conserved between GI and GII genogroups, with Asp506
changed to Pro506 in most other GI and GII strains (Figure S3),
providing the structural basis for the broad recognition of A1431
of GII.4 viruses but not of other norovirus genotypes.
To gain insight into the molecular mechanism of blockade ac-
tivity by antibody A1431, we superimposed the crystal structure
of the P2002-A1431 Fab complex onto the GI.1 capsid structure
(Figure 5E). On the assembled VLP, the P domain dimer exists in
two distinct structural environments, defined by A/B and C/C di-
mers (Prasad et al., 1999). A1431 Fab binding to the A/B dimer
showed no overlap between Fab and either P or S domains,
whereas binding to theC/C dimer showedminor overlap (Figures
5E and 5F). Binding of the A1431 Fab to all equivalent sites on the
VLP showed recognition at the A/B dimer to cover most of
the VLP surface, whereas recognition of the C/C dimer left the
5-fold vertices potentially capable of attaching to HBGAs at
the cell surface (Figure 5G). In both cases, binding at all sites
would lead to substantial antibody-antibody overlap (Figures
5F and 5G), suggesting that A1431 exerts its blockade and
neutralizing activity by binding to only a fraction of potential bind-
ing sites on the VLP. Overall, in contrast to the A1227 binding
site, modeling suggested the A1431 blockade epitope to be
mostly accessible on the capsid surface. Notably, the A1431
epitope did not overlap with identified sites of HBGA recognition,
and therefore, the observed blockade functionality likely stems
either from antibody A1431 sterically inhibiting the approach of
the VLP to the >500 kDa multivalent HBGAs found on MUC2 in
PGM and in human gastric and duodenal tissues (Park et al.,
2015) or from subtle allosteric effects, as reported for another
antibody that docks near to the 1431 binding site (Lindesmith
et al., 2014, 2018b), as defined by epitope mapping. High-reso-
lution structures of broadly reactive and/or neutralizing epitopes
expand our understanding of the HuNoV antigenic landscape
and narrow the search for optimal vaccine candidates. For
instance, whereas antibodies targeting hypervariable P2 epi-
topes (i.e., epitope A) have limited cross-strain ligand-blocking
potency and antibodies recognizing highly conserved epitopes
near the P1-shell-domain interface are highly cross-reactive
but have no blocking potency, the antibodies targeting geno-
type-conserved epitopes at the P1-P2 interface display broad
ligand-binding blocking potency. It should be noted that each
of these antibody classes may contribute to vaccine-induced
protection, and further studies and in vivo models are required
to fully understand the interplay between the antibody targets
and the physiological response.
DISCUSSION
Vaccine-induced immunity relies on the development and main-
tenance of long-term protective antibody titers or serological
memory. The best studied correlate for protective immunity after
HuNoV infection is the development of robust blockade antibody
responses (Lindesmith et al., 2015; Malm et al., 2014; Reeck
et al., 2010). Immune responses to rapidly evolving viral infec-
tions are complex and heavily impacted by pre-exposure his-
tories that shape the antibody response to newly evolved strains
(Belongia et al., 2017; Gostic et al., 2016; Lessler et al., 2012; Lin-
desmith et al., 2017). These studies demonstrate that bivalent
HuNoV vaccines can elicit GII.4 neutralizing antibody responses
in humans, while also structurally defining the highly conserved
GII.4 (1987–2015) epitope recognized by a neutralizing antibody.Here, we demonstrate that the serological repertoire to HuNoV
is oligoclonal and dominated by IGHV3 family antibodies in three
pre-immune individuals who received the vaccine. A large
fraction (6/10) of the serum antibodies that we biochemically
characterized in detail displayed significant binding breadth,
with 4/6 recognizing both GI and GII genotype VLPs. Although
these high-binding-breadth antibodies did not have blockade
activity, they may play a role in protection against HuNoV infec-
tion via Fc-mediated mechanisms. Non-neutralizing antibodies
that protect against infection in animal models are observed at
significant levels in circulation after influenza vaccination (Lee
et al., 2016), and recent studies report the isolation of such anti-
bodies for other viruses as well (Bootz et al., 2017; Henry Dunand
et al., 2016). Current technologies do not allow direct evaluation
of HuNoV Fc-mediated protection.
In donor A, we showed that the most dramatically back-
boosted blockade antibody following vaccination is capable of
blocking VLP-HBGA binding of all examined GII.4 strains circu-
lating between 1987 and 2015 and is potently neutralizing in
the human intestinal enteroid culture system. This antibody
was present in appreciable amounts in the serum prior to vacci-
nation, suggesting that it must have been elicited by an earlier
HuNoV infection. Although lack of successful propagation of his-
toric GII.4 strains limits our ability to test the breadth of GII.4
neutralization, all tested blockade monoclonal antibodies have
also been neutralizing antibodies (Alvarado et al., 2018), indi-
cating that A1431 is also likely cross-GII.4 neutralizing. These
findings reveal that HuNoV infection can induce broad blockade
and neutralizing antibodies and that these antibodies can be
boosted by vaccination (Lindesmith et al., 2012a, 2015).
A1431 is a broad blockade neutralizing human antibody for
which the binding site has now been structurally defined. The
structures of antibodies A1431 and A1227 in complex with the
P domain described here, as well as structures of the GI.1-spe-
cific, HBGA-blocking 5I2 IgA (Shanker et al., 2016) and of the
broadly GII-reactive 5B18 IgG (Hansman et al., 2012) described
previously, support multiple mechanisms of antibody-mediated
recognition and potentially protection from norovirus infection
(Koromyslova et al., 2018). The most abundant ligand-blocking
antibodies recognize hypervariable surface-exposed epitopes
that are frequently mutated as a result of antigenic drift (Debbink
et al., 2012a; Lindesmith et al., 2013, 2015). Antibody binding of
these epitopes blocks the HBGA binding pocket (Shanker et al.,
2016). In contrast, A1431 recognizes conserved residues distal
to the HBGA binding pocket but accessible on the assembled
VLP. Blocking of ligand binding and neutralization likely results
not from direct interference at the ligand-binding site but rather
from either prevention of attachment to the ligand-displaying
surface (i.e., steric effects) or modulation of capsid dynamics
(Lindesmith et al., 2014, 2018b).We note that the unprecedented
blockade breadth of A1431 may be useful for therapeutic pur-
poses, as currently there are no treatment options for chronic
infection or life-threatening HuNoV infection (Ahmed et al.,
2012; Cardemil et al., 2017; Petrignani et al., 2018). The co-crys-
tal structure of A1431 with the P domain potentially provides
avenues by which this antibody may be further improved for
breadth and potency (Diskin et al., 2011; Kwon et al., 2018).
Antibodies like A1227 with broad cross-genogroup binding
have not yet been shown to neutralize or block VLP binding to
HBGAs. These antibodies likely bind to occluded epitopes
available for antibody access during phases of particle assembly
and/or disassembly, intermediates, or rearrangements. Al-
though mechanisms of protection driven by this class of anti-
bodies are undefined, short-term boosting of cross-blockade
antibodies after vaccination (Lindesmith et al., 2015) and mouse
norovirus (MNV) monoclonal antibodies with cross-serotype
neutralization (Kolawole et al., 2017) support the potential for
HuNoV cross-genotype neutralization.
These data provide structural and mechanistic evidence
supporting that the GII.4 component of the Takeda multivalent
norovirus VLP vaccine recalls a memory antibody response
that persists for at least six months, indicating that, similar to
other rapidly evolving RNA viruses, early-life norovirus strain
exposure shapes antibody responses to subsequent norovirus
strains (Lindesmith et al., 2015, 2017). As with influenza, expo-
sure history and genetic background are expected to impact
outcomes differently by age groups, potentially impacting vac-
cine efficacy (Gostic et al., 2016; Lessler et al., 2012). Future
studies are needed to determine additional mechanisms of the
antibody boost to prospective GII.4 strains, as well as the anti-
body response in key vaccine target populations, including the
aged, with a life-time of norovirus exposure but waning immune
responsiveness, and the very young, with no pre-exposure
history and possibly with maternal antibodies. These data are
critical for understanding vaccine performance and population-
based immunity against future pandemic isolates. Cross-block-
ing antibodies like A1431 provide one mechanism of breadth,
and serological repertoire analyses offer robust strategies to
dissect the molecular basis for this and other responses in hu-
man populations. Coupled with blockade, neutralization potency
in the enteroid culture system (Costantini et al., 2018; Ettayebi
et al., 2016), and structural determination of antibody binding
sites, recombinant serum antibodies can provide invaluable in-
formation for immunogen design and vaccination strategies
that phenocopy infection and provide broad, long-term protec-
tion to HuNoV pandemics.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Humans Subjects
Serum and PBMC samples
This study used de-identified human samples under University of North Carolina institutional review board exemption approval
#11-0883. Serum and PBMC samples were collected from two female ages 25 and 46 and one male age 30 participants in a study
conducted by Takeda Vaccines Inc. (Deerfield, IL) (Treanor et al., 2014). Participants in Group A1 received an intramuscular injection
of 5 mg of both GI.1 and GII.4c VLP adjuvanted with 3-O-deacylated monophosphoryl lipid A (MPL, GlaxoSmithKline) and alhydrogel
on day 0 (dose 1) followed by an identical booster vaccination on day 28 (dose 2). This study was done under IRB approval and sub-
jects provided informed consent. The trial was registered at ClinicalTrials.gov (NCT01168401).
Cell lines
BHK -21 cells (ATCC CCL-10, derived from unsexed hamsters) were grown at 37C in 5% CO2 in Minimum Essential Medium with
Earles salts and L-glutamine (Gibco) supplemented with 7% fetal Clone II (Hyclone), non-essential amino acids (Gibco), sodium
pyruvate (Gibco) and Antibiotic-Antimycotic (Gibco).
Microbes
E coli Top 10 with pVR21 plasmid containing norovirus capsid genes were propagated at 30C in the presence of 0.1mg/ml carbe-
nicillin in Luria-Bertani broth. For full IgG expression and characterization, VH and VL plasmids were transfected into 30 mL cultures
of Expi293F cells (Invitrogen) at a 1:2 ratio and incubated at 37C and 8% CO2 for 7 days.
For protein crystallization, P-domains were transfected into E.coli BL21 (DE3) (Agilent Technologies) and plated onto Luria-Bertani
plates with 50mg/mL Ampicillin (LB-Amp). VH and VL chains were cotransfected into Expi293F cells (ThermoFisher) using a 3:1 ratio
of Turbo293 transfection reagent (Speed Biosystem) to plasmid. Cells were incubated at 37C, 5% CO2, 130 rpm shaking, 70% hu-
midity for 18 h and subsequently boosted with 80mL of AbBooster (Abi Scientific).
METHOD DETAILS
Ten percent stool filtrate
This investigation was determined by CDC to be public health non-research, and therefore was not subject to institutional review
board review. Ten percent stool suspension was prepared by adding 0.5 g of GII.P16-GII.4 Sydney positive whole stool to 4.5 mL
of PBS. The stool suspension was vortexed for 30 seconds, kept at room temperature for 5 min and vortexed again. Sample was
sonicated and solids were removed by centrifugation for 10 min at 10,000 x g. The supernatant was serially filtered through 5 mm,
1 mm, 0.45 mm, and 0.22 mm filters. The resulting 10% stool filtrate was aliquoted and stored at 70C.
Human intestinal enteroid culture (HIE)
HIE cells were kindly provided by Dr. Mary K. Estes, Baylor College of Medicine, Houston, Texas. Adult (female) secretor positive
jejunal HIE cultures were grown as undifferentiated 3D cultures as described previously with minor modifications (Costantini
et al., 2018; Ettayebi et al., 2016). Briefly, HIEs were recovered from liquid nitrogen (LN2), suspended in 20 ml of Matrigel (Corning),
plated in a single well of a 24 well plate, and grown as 3D cultures in 500 mL IntestiCult Organoid Growth Medium (Human)
(STEMCELL Technologies) supplemented with 10 mM Y-27632 (Sigma-Aldrich). Media was refreshed every other day. Highly dense
3D cultures were passaged once per week. To passage, HIE were taken up in ice-cold complete medium without growth factors
(CMGF-), broken up by repeating pipetting cycles, suspended in Matrigel (Corning), and plated in 24 well plates. CMGF- compro-
mises Advanced Dulbecco Modified Eagle Medium (DMEM)/F12 supplemented with 1% GlutaMAX, 1% Penicillin/Streptomycin,
1% 1MHEPES. If single cell suspension was required, HIE were taken up in ice-cold 0.5mMEDTA and broken up by repeating pipet-
ting cycles. After centrifugation (200 x g for 5 min at 4C), single cell suspension was obtained upon treatment of the HIE with 0.05%
Trypsin/0.5mM EDTA (Invitrogen) for 3–4 min at 37C. Trypsin was then inactivated by adding CMGF- /10% FBS to the cell suspen-
sion. Cell suspensions were prepared by pipetting with a P1000 pipet and passing the cells through a 40 mm cell strainer. The cells
were pelleted for 5min at 400 x g, suspended in 100 ml of in IntestiCult Organoid GrowthMedium (Human) (STEMCELL Technologies)
supplemented with 10 mM Y-27632 (Sigma-Aldrich) and plated as undifferentiated monolayers in collagen IV (Sigma-Aldrich)
pre-coated 96 well plates. After 24 h, culture medium was replaced with differentiation medium to induce cell differentiation.
Differentiation media compromises CMGF- ,1:100 B27 supplement, 1:50 N2 supplement, 1:1000 mouse epidermal growth factor
(all Invitrogen), 1 mM n-Acetyl-L-cysteine, 10 nM [Leu15]-Gastrin, 10 mM Y-27632 (all Sigma-Aldrich), Noggin 20%, (conditioned
home-made medium), 500 nM A83-01 (Tocris). Cells were differentiated for 4 days. Media was refreshed every other day.
High-throughput sequencing of BCR transcripts
Frozen PBMCs were thawed at 37C, resuspended in RPMI-1640 (Fisher) supplemented with 10% Fetal Bovine Serum (FBS) and
20 U/mL deoxyribonuclease I (Roche), concentrated by centrifugation (300 x g for 15 min at 20C), and allowed to recover in
4 mL media at 37C for 30 min. The cells were then split: half were dedicated to BCR heavy chain transcript sequencing, and half
were used to identify the native VH/VL repertoire.
VH Sequencing
Cells were diluted with 10 mL of cold buffer (phosphate buffered saline supplemented with 0.5% BSA and 2 mM EDTA) and pelleted 
via centrifugation (300 x g for 15 min at 4C). The supernatant was decanted, and the cells were resuspended in 1mL of TRIzol reagent 
(Thermo Fisher). RNA was extracted using RNeasy (Qiagen), and first strand cDNA was synthesized from 500 ng total RNA using 
SuperScript II (Invitrogen). IgM and IgG heavy chain repertoires were amplified using a multiplex primer set (Table S3) under the 
following conditions: 2 min at 94C; 4 cycles of 94C for 30 s, 50C for 30 s, 72C for 30 s; 4 cycles of 94C for 30 s, 55C for 
30 s, 72C for 30 s; 22 cycles of 94C for 30 s, 63C for 30 s, 72C for 30 s; 72C for 7 min; hold at 4C (Ippolito et al., 2012) and 
sequenced by 2x300 paired-end Illumina MiSeq.
VH/VL Sequencing
Total B cells were isolated from PBMCs using the Human Memory B Cell Isolation Kit (Miltenyi Biotec) with an LD column according to 
the manufacturer’s instructions. B cells were then coemulsified with oligo d(T)25 magnetic beads (New England Biolabs) and lysis 
buffer (100 mM Tris pH 7.5, 500 mM LiCl, 10 mM EDTA, 1% lithium dodecyl sulfate, and 5 mM dithiothreitol) using a custom-designed 
flow focusing device as described (McDaniel et al., 2016). The magnetic beads were washed, resuspended in One step fast qRT-PCR 
solution (VWR) supplemented with an overlap extension VH and VL primer set as described (McDaniel et al., 2016), emulsified, and 
subjected to overlap-extension RT-PCR under the following conditions: 30 min at 55 C followed by 2 min at 94 C; 4 cycles of 94 C 
for 30 s, 50 C for 30 s, 72 C for 2 min; 4 cycles of 94 C for 30 s, 55 C for 30 s, 72 C for 2 min; 32 cycles of 94 C for 30 s, 60 C for 
30 s, 72 C for 2 min; 72 C for 7 min; hold at 4 C. VH/VL amplicons were then extracted from the emulsions, amplified using nested 
PCR, and sequenced by 2x300 Illumina MiSeq.
Isolation of HuNoV specific antibodies
HuNoV VLP (GII.4c, 1 mg) was immobilized on 250 mg N-hydroxysuccinimide (NHS)-agarose beads (Thermo Fisher) by overnight 
rotation at 4C. The conjugated resin was washed with PBS, and unreacted NHS groups were blocked with 1M ethanolamine, pH 
8.3, for 20 min at RT. The beads were washed with PBS, packed into a 5 mL column, washed with 10 column volumes (cv) of 4M 
urea in PBS, and finally washed with 20 cv PBS. Total IgG was isolated from each serum sample using melon gel purification (Thermo 
Fisher) according to the manufacturer’s instructions. IgG was then passed over the affinity column in gravity flow mode to capture 
GII.4c VLP-specific antibodies. Flow through was collected and reapplied to the column five times. The column was washed with 
PBS with 2 cv followed by 1 cv of water before elution in 12-1 mL fractions of 5% formic acid. 10 mL of each elution fraction was 
neutralized with 100 ml of 25x PBS in 2% milk and analyzed via ELISA against GII.4c VLP (antibodies bound to immobilized GII.4c 
were detected using goat anti-human IgG Fcperoxidase antibody (Invitrogen)). Fractions containing antigen-specific antibodies 
were pooled, concentrated under vacuum, and resuspended into 50 mL of 100 mM Tris-pH 8.
Sample preparation and LC-MS/MS analysis
For each sample, the flow through and antigen enriched elution were denatured in 1:1 (v/v) trifluoroethanol, reduced with 5 mL 
tris(2-carboxyethyl)phosphine (TCEP, 110 mM) in the dark at 55C for 45 min, and alkylated with 32 mM iodoacetamide by incubating 
in the dark for 30 min. Samples were diluted 10x into 50 mM Tris (pH 8.0) and digested with trypsin (1:10 trypsin/protein) for 5 h at 
37C. Formic acid (0.1%) was used to quench the reaction. The solution was then concentrated, desalted using a C18 Hypersep 
SpinTip (Thermo) according to the manufacturer’s instructions, and submitted for LC-MS/MS.
Peptides were separated by reversed-phase chromatography (Dionex UltiMate 3000 RSLCnano System with Dionex Acclaim 
PepMap RSLC C18 column, Thermo Scientific) and analyzed online by nano–electrospray ionization–MS/MS on Orbitrap Velos 
Pro (Thermo Scientific). MS1 scans were collected in the orbitrap at a resolution of 60,000 Å , and the ions with >+1 charge were 
fragmented by collision-induced dissociation with up to 20 MS2 spectra collected per MS1.
SEQUEST (Proteome Discoverer 1.4, Thermo Scientific) with previously described settings (Williams et al., 2017) was used to 
search the spectra against a patient-specific protein database constructed from the full-length VH and VL sequences, Ensembl 
human protein-coding sequences, and common contaminants (maxquant.org). PSMs were filtered with Percolator (Proteome 
Discoverer 1.4) at a false discovery rate of <1% and filtered for average mass deviations <1.5 parts per million. Peptides mapping 
to the CDR-H3 region of unique antibody lineages were grouped, and the relative abundances of the corresponding peptide matches 
were determined by the sum of the extracted ion chromatograms (XIC) of the respective precursor ions. Relative abundances were 
multiplied by the patient specific anti-GII.4c titer to calculate the amount of GII.4c specific clonotypes in serum.
Antibody expression and purification
Selected antibody sequences were purchased as gBlocks gene fragments (Integrated DNA Technologies) and cloned into a custom-
ized pcDNA3.4 vector (Invitrogen) containing human IgG1 Fc regions. VH and VL plasmids were transfected into 30 mL cultures of 
Expi293F cells (Invitrogen) at a 1:2 ratio and incubated at 37C and 8% CO2 for 7 days. The supernatant containing secreted 
antibodies was collected following centrifugation (1000 g for 10 min at 4C), neutralized, and filtered. Antibodies were isolated using 
Protein G Plus agarose (Pierce Thermo Fisher Scientific) affinity chromatography, washed with 20 column volumes of PBS, eluted 
with 100 mM glycine-HCl pH 2.7, and neutralized with 1 M Tris-HCl pH 8.0. The antibodies were then concentrated and buffer 
exchanged into PBS using 10,000 MWCO Vivaspin centrifugal spin columns (Sartorius).
Production of Virus Like Particles
For production of the VLP for this study, HuNoV ORF2 genes were synthesized by Bio Basic Inc (Markham, ON) with ApaI and AcsI
restriction sites for direct insertion into the VEE replicon vector pVR21. The sequence-verified pDNA was propagated in Ecoli Top 10
(Invitrogen). pDNA was purified with QIAprep Miniprep kit (Qiagen). Purified pDNA was linearized with NotI, agarose gel purified with
QIAquick Gel Extraction kit (Qiagen) and mRNA generated using mMESSAGE mMachine T7 transcription kit (Invtirogen). Message
RNA was electroplated into BHK cells (ATCC CCL-10) for production of VLP (Agnihothram et al., 2018; Debbink et al., 2013).
After 27 h, cells were washed and lysed in 1% Triton X-100 in PBS plus cOmplete EDTA-free protease inhibitor cocktail (Roche)
and cell lysates layered above a cushion of 40% sucrose in PBS. VLP were purified into the cushion by ultracentrifugation at
120,000 x g for 75 min and stored at -80C in 40% sucrose/PBS. Protein concentration was determined by BCA assay (Pierce).
VLPs were verified for particle integrity by ligand and antibody binding and visualization by electron microscopy of40nm particles.
Antibody functional assays
EIA and blockade antibody assays were performed at described (Lindesmith et al., 2018a) at 0.25 mg/ml VLP. EIA plates were coated
with VLP in PBS for 4 h and blocked over night at 4C in 5% dry milk in PBS-0.05% Tween-20 before the addition of decreasing
two-fold serial dilutions of mAb at 37C. Bound mAb was detected by anti-human IgG-HRP (GE Healthcare) and color developed
with 1-Step Ultra TMB ELISA HRP substrate solution (Thermo-Fisher). Similarly, VLPs were pretreated with decreasing concentra-
tions of mAb for 1 h and added to pig gastric mucin type III (Sigma Aldrich, St. Louis, MO) coated plates for 1 h. Bound VLP was
detected by anti-VLP rabbit hyperimmune sera followed by anti-rabbit IgG-HRP (GE Healthcare) and color developed as above.
Percent control binding is defined as the binding in the presence of antibody pretreatment compared to the binding in the absence
multiplied by 100.
P domain expression and purification
The gene for the P-domain of HuNoV GII.4.2002 (accession number: AFJ04708) corresponding to amino acids 225-530 was
synthesized by GenScript and codon optimized for E. coli expression. The P-domain gene was cloned in pMal-C5X plasmid
(NEB) with a HRV-3C cleavage site between the MBP-6xHis and the P-domain (Nucleotide sequence: CATCACCACCACCAT
CACGGTTCTGGTCTGGAAGTTC-TGTTCCAGGGGCCCTCC). The plasmid was transformed into E.coli BL21 (DE3) (Agilent
Technologies) and plated onto Luria-Bertani plates with 50mg/mL Ampicillin (LB-Amp). A single colony was used to inoculate
100mL of LB-Amp. After incubation for 18 h at 37C and 210 rpm shaking, 10 mL of culture was used to inoculate 1L of LB-Amp
at 37C and 210 rpm shaking. When OD600 reached 0.7, flasks were cooled for 30 min in ice/water bath. Flasks were subsequently
incubated at 18C and 210 rpm shaking for 30 min before induction with 0.5mM IPTG (Isopropyl b-D-1-thiogalactopyranoside). After
18 h, cells were harvested by centrifugation at 10,000 x g for 20min at 20C. Pellets from 1L cell culture were resuspended in 40mL of
PBS with addition of 150mM of NaCl and flash frozen in liquid nitrogen. Cell pellets were stored at -80C until further use.
Pellets from 1L of cell culture were thawed on ice and supplemented with one tablet of protease inhibitors (Roche cOmplete
EDTA-free cocktail) and 1mg/mL of Lysozyme (Sigma-Aldrich). Cell slurry was kept on ice and sonicated with a Branson Sonifier
SFX150 equipped with micro-tip (5 seconds ON, 30 seconds OFF for a total process time of 2 min). Lysed cells were centrifuged
at 38,000 x g for 45 min at 4C. Clarified lysate was batch bound to 4mL of Ni-resin (Roche cOmplete His-Tag Purification Resin)
for 1 h at 4C with end-over-end rotation. Resin slurry was loaded on a plastic column and allowed to flow by gravity. Resin was
sequentially washed with 40mL of PBS and 40mL of PBS with 20mM Imidazole (pH 8.0). Bound protein was eluted with PBS with
200mM Imidazole (pH 8.0) and elution collected in 5mL fractions. Protein concentration was determined by absorption at 280nm
using a calculated extinction coefficient of 102010 M1 cm1. Fractions with highest concentration were pooled and 20U of
HRV-3C protease (Millipore-Sigma) were added. Cleavage reaction was subsequently dialyzed in 10 kDa MWCO cassette (Thermo-
fisher Slide-A-Lyzer) overnight against 4L of buffer containing 25mM Tris-HCl (pH 7.5), 150mM NaCl and 5mM b-mercaptoethanol.
Complete cleavage of MBP-6His from P-domain was confirmed by SDS-PAGE gel shift after Coomassie staining. Cleavage reaction
was bound to 2mL of Ni-resin and incubated with end-over-end rotation for 1 h. Resin was loaded onto plastic column and
flow-through containing cleaved P-domain was collected. Resin was washed with 5mL of dialysis buffer and both flow-throughs
were pooled and concentrated to around 10mg/mL in 10kDa MWCO Amicon Ultra (Millipore-Sigma). Concentrated sample was
loaded onto Superdex-200 Increase 10/300 GL (GE-healthcare) equilibrated with 25mM Tris-HCl (pH 7.5), 150mM NaCl and the
peak corresponding to P-domain (elution volume 15.5mL) was collected. Purification was assessed by SDS-PAGE and purified
P-domain was concentrated to 5mg/mL in 10kDa MWCO Amicon Ultra and stored at 4C until further use.
Antibodies A1227 and A1431 were produced as previously described (McLellan et al., 2011). Briefly, heavy chain plasmids, con-
taining the HRV3C cleavage site in the hinge region, and light chain plasmids were cotransfected in Expi293F cells (ThermoFisher)
using a 3:1 ratio of Turbo293 transfection reagent (Speed Biosystem) to plasmid. Cells were incubated at 37C, 5% CO2, 130 rpm
shaking, 70%humidity for 18 h and subsequently boostedwith 80mL of AbBooster (Abi Scientific). Temperature was lowered to 33C
and expression was continued for additional 6 days. Cells were pelleted at 10000 x g, 20C for 45 min and pellet discarded. Super-
natant containing secreted antibody was supplemented with two tablets of protease inhibitors (Roche cOmplete EDTA-free). All
subsequent steps were performed at 4C. Cell supernantant was loaded by gravity onto 5ml of Protein A slurry (GE MabSelect)
pre-equilibrated with PBS. Resin was washed with 50 mL of PBS and eluted in 1mL fractions with Pierce IgG Elution buffer. Elution
was immediately neutralized with 1M Tris-Cl, pH 8.0 (final concentration 0.1M). Fractions with highest concentration (determined by
A280 absorption) were pooled and 40U of HRV-3C protease (Millipore-Sigma) were added. Cleavage reaction was allowed to
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proceed for 18 h at 4C with end-over-end rotation. Cleavage reaction was assessed by SDS-PAGE before proceeding to next step. 
One mL of Ni-resin (Roche cOmplete His-Tag Purification Resin) loaded onto plastic column and overlaid with two mL of protein A 
resin. Ni-resin was used to capture His-tag, while protein A resin was used to capture free Fc. Both resins were equilibrated with PBS. 
Cleavage reaction was loaded by gravity onto resins and flow-through was collected. Resins were washed with 10mL of PBS and the 
second flow-through pooled with the first. Protein concentration was assessed by absorption at 280nm and removal of Fc and His-
tag was verified after SDS-page and Coomassie staining. Purified Fab were concentrated to 10mg/mL in 10kDa MWCO Amicon Ultra 
(Millipore-Sigma) and purified on a Superdex-200 Increase 10/300 GL (GE-healthcare). Fractions containing pure Fab were pooled, 
concentrated to 10mg/mL in 10kDa MWCO Amicon Ultra (Millipore-Sigma) and stored at 4C until further use.
Crystallization of Fab complex with P2002
Purified P2002 was mixed with 1.5-fold molar excess of purified Fab A1227 or Fab A1431 and incubated at 20C for 1 h with end-
over-end rotation. The mixture was injected onto Supredex 200 Increase 10/300 GL equilibrated with 25mM Tris pH 7.5, 150mM 
NaCl. Both complexes had a retention volume of around 12.3mL, consistent with two Fabs binding to one P-domain dimer. The frac-
tions containing the complex were pooled and concentrated to 5mg/mL in MWCO 10kDa and immediately used for crystallization 
trials. The P2002-A1227 Fab complex was mixed with an equal volume of precipitant solution (10% polyethylene glycol 4000, 
0.1M Tris pH 8.5, 50mM proline) and crystallized by sitting-drop vapor diffusion over the precipitant solution at 20C. Rod-shaped 
crystals formed after 2 days. Crystals were harvested using Dual-Thickness MicroLoops (MiTeGen), cryoprotected using 30%
ethylene glycol and immediately flash frozen in liquid nitrogen. The same procedure was used to crystallize the P2002-A1431 Fab 
complex, except the precipitant solution contained 10% polyethylene glycol 8000 and 0.1M CHES pH 9.5. Rod-shaped crystals 
formed after 2 days.
Structure determination and analysis
All diffraction data were collected at 100 K and 1.000 Å wavelength at the SER-CAT beamline ID-22 (Advanced Photon Source, 
Argonne National Laboratory) and processed with the HKL2000 suite (Otwinowski and Minor, 1997). A complete dataset was 
collected for the GII.4.2002 P domain-A1227 Fab complex to 2.6 ˚ using 0.25 oscillations and translating the crystal to different 
spots throughout data collection. A complete dataset was collected for the GII.4.2002 P domain-A1431 Fab complex to 3.1 
from a single crystal using 0.5 oscillations. Each structure was solved by molecular replacement with the program PHASER (McCoy 
et al., 2007) using PDB ID 4OOV for the apo structure of GII.4.2002 P domain and PDB ID 3EYQ for the Fab as search models. Iterative 
cycles of model building and refinement were performed using COOT (Emsley and Cowtan, 2004) and PHENIX (Adams et al., 2004). 
Data collection and refinement statistics are shown in Table S2.
GI, GII and GII.4 sequence conservation scores were calculated using the AL2CO server (Pei and Grishin, 2001) and mapped onto 
the GII.4 P domain surface as described previously (Hansman et al., 2011). Buried surface area calculations and interface analyses 
were carried out with PISA (Krissinel and Henrick, 2007). Structure figures were prepared using the programs The PyMOL Molecular 
Graphics System, Version 2.0.5 Schrö dinger, LLC and Chimera (Pettersen et al., 2004).
Neutralization Assay
Norovirus antibody neutralization
Serial dilutions of each mAb were prepared in complete medium without growth factors (CMGF) and pre-incubated with GII.P16-
GII.4 Sydney stool filtrate (3.1 x 105 viral genomic copies). After 1 h incubation at 37C and 5% CO2, samples were diluted 1:2 in 
CMGF supplemented with 1000 mM sodium glycochenodeoxycholate (GCDCA; Sigma-Aldrich) plus 100 mM ceramide (Santa 
Cruz Biotechnology). Duplicated, 100% confluent 4-day old differentiated monolayers, were inoculated. After 1 h incubation at 
37C and 5% CO2, monolayers were washed twice with CMGF and 100 ml of differentiation medium containing 500 mM GCDCA 
plus 50 mM ceramide was added to each well. For each set of infections, one plate was immediately frozen at -70C and a duplicate 
plate was incubated at 37C, 5% CO2 for 24 h and frozen at -70C.
For each monoclonal antibody, 4 independent experiments with 2 technical replicates for each mAb dilution on each experiment 
were performed. Neutralization was expressed as a measure of the reduction in viral genomic copies (as percentage) when 
compared to a control (no mAb) within each assay using real-time RT-qPCR.
Norovirus detection and quantification
Viral RNA was extracted from cultures (cells and media) at 1 h post-infection (hpi) and 24 hpi using the KingFisher instrument and 
MagMAX - 96 Viral RNA Isolation Kit (Applied Biosystems) according to the manufacturer’s instructions. Norovirus RNA was detected 
by GI/GII TaqMan real-time RT-PCR (Cannon et al., 2017). Standard curves were generated using 10-fold serial dilutions of GII.4 
Sydney RNA transcripts.
QUANTIFICATION AND STATISTICAL ANALYSIS
Antibody EC50 and IC50 were determined from log-transformed non-linear, dose-response sigmoidal curve fit data using 
GraphPad 7.02 (Lindesmith et al., 2015; Lindesmith et al., 2017). Antibody binding by EIA less than 0.2 OD at 2 mg/ml or blockade 
assays IC50 >2mg/ml was scored as negative for binding. Samples were tested in duplicate in a minimum of two independent 
experiments and the results reported in Figures 2 and 3.
DATA AND SOFTWARE AVAILABILITY
The datasets generated during the current study are available from the Lead Contact upon reasonable request. The accession
numbers for the amino acids sequence of HuNoV strain capsids reported in this paper are GenBank: AAB50466.2 (GI.1),
AFK75851.1 (GI.3), AFK75852.1 (GI.4), AFJ04707.1 (GII.4 1997), AFJ04708.1 (GII.4 2002), AFJ04709.1 (GII.4 2006b), AFV08795.1
(GII.4 2012), APA31970.1 (GII.4 2015), AFS33555.1 (GII.1), AAN08112.1 (GII.2), AFK75854.1 (GII.3), AAN05735.1 (GII.14),
AKB94547.1 (GII.17), MK614455 (GII.4c), MK614084 (GII.4 2006a.581 virus-like particles), MK614085 (GII.4 2006a.581.A4A
virus-like particles), MK614086 (GII.4 2006a.581.A4B virus-like particles), MK614081 (GII.4 1987. 2012A virus-like particles),
MK614082 (GII.4 1987. 2012D virus-like particles), MK614083 (GII.4 1987. 2012E virus-like particles). The accession numbers for
the atomic coordinates and structure factors for the reported crystal structures are Protein Data Bank (PDB): 6N81 and 6N8D.
